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severity
José Araújo‑Martins 1,2*, Carlos Brás‑Geraldes 3,4 & Nuno Neuparth 2
Although the pathophysiology of nasal polyposis is incompletely understood, rhinologists have 
seldom studied it with rhinomanometry or peak nasal inspiratory flow (PNIF) due to technical 
limitations and the perception that polyp size might impair reproducibility and the usefulness of 
recordings. The objective of this study is to assess how measures of rhinomanometry and PNIF relate 
to disease activity. Nineteen patients with polyps, 15 patients with chronic sinusitis without polyps 
and 11 negative controls were evaluated with active anterior rhinomanometry and PNIF. Sinusitis and 
polyp patients were re‑evaluated after medical treatment. Polyp patients had the highest median 
Lund‑Mackay score (14) and a median Johansen score of 1. PNIF and its variation after treatment 
were also lowest in this group (median 90 L/min before and after treatment; median variation of 
0 L/min). Nasal resistance was similar between groups, and only correlated with Johansen score 
(Spearman = 0.517, p = 0.048) after treatment. Our study suggests that evaluating polyp patients using 
rhinomanometry and PNIF may provide useful and reproducible data. Several findings considered 
together suggest that polyp size is not the main determinant of nasal functional changes in these 
patients, warranting further studies to verify whether PNIF changes reflect sinus inflammation or 
merely airway obstruction.
Nasal polyposis (NP) is a chronic nasal inflammatory disease and is considered an endotype of chronic rhinosi-
nusitis (CRS)1–3. The prevalence of NP is reported to be 1–4% of the general  population1,4,5, reaching as high as 
32% in cadaver  studies6. The average incidence of symptomatic NP has been estimated to be around 0.86 and 
0.39 patients/1,000 individuals per year in male and female patients,  respectively7. Medical or surgical treatment 
significantly improve quality of life but surgery may be required in up to 50% of  patients8 and 8–25% of those may 
require revision  surgery1,9. The socio-economical cost of CRS parallels those of diabetes mellitus, chronic obstruc-
tive pulmonary disease and coronary artery  disease10. Poorly controlled CRS is estimated to cost around 2000€ 
per year, per  patient11, based on direct health services use, and indirect costs of absenteism and presenteism. The 
worsening of associated co-morbidities (ex: asthma, sleep apnea, etc.) also represents an economical burden.
Rhinologists agree that research to determine the most effective treatment plan is a  priority12 and should be 
encouraged by proper  authorities13, with emphasis on the principles of precision medicine and patient centered 
 care3. These explicitly recommend the use of relevant clinical biomarkers to elaborate personalized treatment 
plans.
The central role of epithelial cell lesion in the pathogenesis of NP has long been  recognized14 and mucosal 
inflammation has been extensively studied and established as the cause rather than the consequence of NP in 
experimental  models15,16. However, little was investigated on the effect of nasal ventilation in NP. Consequently, 
no nasal ventilation variables are considered as possible disease biomarkers in NP. Epithelial metaplasia and cili-
ary dysfunction were noted with increased local nasal  airflow17. Known mesenchimal cell mechano-transduction 
 mechanisms18 as well as analogies between endothelial cell transmembrane proteins and shear stress lesion 
with NP nitric oxide and epithelial disaggregation mechanisms suggest that ventilation could have a role in NP 
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pathogenesis. Recently, computerized fluid dynamic models reinforced this idea by demonstrating increased 
positive pressure areas where polyps were  found19. In short, several studies suggest that nasal ventilation may 
indeed influence the behaviour of NP.
There are several techniques to objectively evaluate nasal ventilation, of which rhinomanometry and peak 
nasal inspiratory flow (PNIF) are the best studied. Several guidelines, panel reports and consensus help research-
ers and clinicians to apply these techniques in a standardized and comparable  manner20–22. A recognized limita-
tion is the inability to obtain measures in a setting of severe obstruction, and polyps may also limit the reliability 
of results because of reduced reproducibility due to variable size between individuals and throughout time, related 
to disease behaviour or treatment effect, as reported  previously23. The future in nasal functional evaluation is 
moving towards the use of computerized analysis of nasal anatomy based on fluid dynamics  models19,24, or, pos-
sibly new methods for non-invasive evaluations such as those based on  thermistors25,26, that have been adapted 
from other areas. Such methods may provide very refined analysis of the patients’ breathing function without the 
need for artificial ventilation patterns or patient compliance. However, this will also come at the cost of equip-
ment, time, dedicated personnel and specific training to do so. Moreover, they still lack clinical implementation 
and validation. PNIF, on the other hand, is a well-established method to evaluate nasal function objectively that 
can be performed by the otolaryngology surgeon during any consultation. This will bear minimal costs and the 
results will be available immediately. For these reasons PNIF may prove to be an indispensable tool in rhinology 
practice, as it has been on clinical  research27.
In summary, NP is a socially relevant disease and new disease biomarkers must be identified to help manage 
treatment in a personalized manner. Few studies have reported results from PNIF and/or rhinomanometry in 
NP patient  cohorts23,28–31 and, to the best of our knowledge, none have specifically tried to measure the effect of 
polyp size on those techniques. In light of the previous considerations, our aim is to evaluate if polyp size alters, 
or not, PNIF and rhinomanometry results, which has implications in the validity of testing those techniques as 
NP disease biomarkers in the future.
We hypothesize that polyp size does not significantly change the results from nasal functional studies. To 
test that hypothesis, PNIF and rhinomanometry measurements were compared against polyp size. Addition-
ally, the same measurements were recorded in patients with CRS or without nasal mucosa disease. Comparing 
those groups against NP patients, will help to answer the question of whether the presence of polyps is inevitably 
associated with poorer nasal ventilation.
Methods
Study design. This is a cross-sectional and prospective study. Three patient groups were considered for 
recruitment: negative controls (NC), without nasal mucosa disease, positive controls, with CRS (without polyps) 
and patients with NP. This project respected all national and European regulations and legislation concern-
ing good medical practice, clinical research, bioethics and data protection. The study protocol was submitted 
to and approved by the Ethics Committees from NOVA Medical School and Centro Hospitalar do Oeste. All 
patients gave their written and informed consent to participate in the study. Given the exploratory nature of 
the study and scarce information in the literature, a convenience sample size was decided based on examples 
of published  studies32,33. The study was developed in the context of a PhD project and funded by a prize from 
the NOVARTIS|Excellence in Medicine program and a grant from NOVA Saúde (Universidade Nova de Lisboa 
Rectorate).
Setting. The study takes place in an Otolaryngology and Head and Neck Surgery clinic in Hospital de Tor-
res Vedras—Centro Hospitalar do Oeste. All eligible patients who met the inclusion criteria were sequentially 
enrolled after informed written consent was obtained. The main author was responsible for recruiting and evalu-
ating (clinical, endoscopic, PNIF and rhinomanometry measurements) every study participant.
Patient recruitment and follow‑up. Patients were evaluated and recruited to each group according to 
the diagnostic criteria published in  EP3OS1. Those patients who met the following exclusion criteria were not 
enrolled in the study: patients unable to provide written informed consent,with congenital or pos-traumatic 
anatomic abnormalities,proven or suspected nasal neoplasia; choanal, antro-choanal or isolated single nasal 
polyps; isolated maxillary or sphenoid sinusitis. All patients had a baseline evaluation with PNIF and rhinoma-
nometry and were medically treated according to the recommendations in the EP3OS document. Patients with 
CRS were provided with systemic and nasal topical corticosteroid and long-term chlarithromycin. Patients with 
NP were provided with the same and also leukotriene antagonists. Patients in the CRS and NP were re-evaluated 
5–8 weeks after beginning medical treatment.
Nasal functional evaluations. Active anterior rhinomanometry was performed using a NR6 manometer 
from GM  Instruments® with the research software (4-phase curve analysis) and PNIF was performed with a 
Youlten debitometer, according to published consensus  recommendations20,21. A graphic depiction of the equip-
ment and recording set-ups may be found in these  guidelines21. A twenty minutes acclimatization period was 
respected and all evaluations were performed before and after nasal decongestion with topical xylomethazoline 
spray (Vibrocil  Actilong®)—a puff in each nostril, followed by another 5 min after, and measurements ten min-
utes after the second puff. All recordings took place in the same room at an average temperature between 20° and 
25° and although complete atmospherical standardization would be ideal, it is not strictly  necessary22.
Study variables and analysis. Age, gender and smoking status were registered as base population char-
acteristics. The extension of sinusitis was measured using the Lund-Mackay score from computed tomographic 
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scans of the sinuses (each side and total). Polyp size was recorded considering Johansen’s  scale34, modified 
according to Kramer et al.35, in order to distinguish large (polyp size 3) from obliterative lesions (polyp size 
4): 0—no polyps,1—polyps not reaching the middle turbinate lower border,2—polyp not reaching the inferior 
turbinate lower border; 3—beyond the inferior turbinate lower border; 4—complete obstruction of the nasal 
airway. PNIF values were recorded before and after decongestion and the difference in the best of these values, 
before and after treatment was calculated (ΔPNIF). From the rhinomanometry evaluations we recorded resist-
ance at 150 Pa from the left (Re) and right (Rd) nasal cavities and whole nose (Rt), as well as Broms angle (Ve, 
Vd and Vt) in both inspiratory and expiratory phases.
A descriptive statistics study was performed for all variables. Continuous variables are presented with the 
average and standard deviation or median and interquartile range, as appropriate, and categorical variables are 
presented as proportions. Parametric or non-parametric independent or related samples tests were used with 
Bonferroni correction, according to whether the distribution of the data in each variable was normal or not. The 
Wilcoxon test was used to compare measurements before and after decongestion and the Chi-squared or Fisher 
test were used to compare categorical variables. A p-value < 0.05 was considered statistically significant and nasal 
cavities were compared independently from the patient (i.e. as if they were “different separate individuals”). Effect 
sizes for comparisons were calculated and interpreted according to Cohen criteria, as described by  Pallant36.
Ethical approval. All procedures performed in this study involving human participants were in accord-
ance with the ethical standards of both institutional research committees (NOVA Medical School and Centro 
Hospitalar do Oeste) and with the 1964 Helsinki declaration and its later amendments and comparable ethical 
standards.
Informed consent. Informed consent was obtained from all individual participants included in the study.
Human research and informed consent. The study was approved by the institutional review board 
and namely by the ethics committee from NOVA Medical School and Centro Hospitalar do Oeste. All study 
participants were volunteers and were only included after providing their free and informed consent by writing.
Results
Patient recruitment. Eleven healthy patients were evaluated, as well as 16 CRS patients (one lost for fol-
low-up after beginning treatment and another recruited only after treatment) and 19 NP patients (two lost for 
follow-up)—see study flowchart in Fig. 1. When data is missing (due to absent records or inability to measure 
functional variables), n values for each analysis may differ from N values for each group.
Population characteristics. The individual descriptive characteristics for all patients can be found in 
Table 1. Significant differences were found regarding age, smoking status and Lund-Mackay scores. Age differ-
ence is significant between groups (p = 0.016) as well as smoking status (p = 0.027), due to the characteristics of 
the NP group. The proportion of smokers between genders was not significantly different (8/22 females vs 7/24 
males, p = 0.755). Lund-Mackay scores are significantly different between groups, although, despite the observed 
trend for higher values in the NP group, statistical significance could not be reached when comparing CRS to NP 
patients (p values between 0.07 and 0.17).
Polyp size. Average polyp sizes and their changes with treatment are described in Table 2. One patient had 
bilateral score 4 polyposis in the first evaluation. Three patients showed complete regression of their polyps and 
an average change of 0.5 in score in each side was observed after treatment, which was significant (right, left and 
total: p = 0.020, p = 0.023 and p = 0.009, respectively).
PNIF. A preliminary analysis concluded that there was no significant difference between PNIF values 
recorded before and after decongestion. With that in mind, we opted to discuss and present baseline results 
before decongestion, except where noted otherwise (Table  3). The change in PNIF after treatment is shown 
as ΔPNIF. A significant difference between NC patients and CRS or NP patients was evident and significant 
(p = 0.010). After treatment, sinusitis and polyp patients showed significantly different average PNIF recordings 
(p = 0.043). Although other comparisons could not reach statistical significance, the data suggest a clinically sig-
nificant trend for ΔPNIF to be lower in NP patients (35 L/min in sinusitis vs 0 L/min in polyps). Furthermore, 
PNIF change after treatment was significant in CRS patients (p = 0.048), but not NP patients (p = 0.674).
Rhinomanometry. All the recordings from rhinomanometry produced a large volume of data that was 
submitted to an exploratory analysis. Resistance and flow parameters improved significantly after decongestion 
in the control group. However, no significant changes were found from the effect of decongestion or the respira-
tory cycle phase in sinusitis and polyp patients. Also, a multiple variable, mixed-effect model analysis reinforced 
this impression (unpublished data). To abbreviate and avoid redundancy, rhinomanometry measurements are 
presented in Table 4 and concern the pre-decongested and inspiratory phase results. Adequate readings were 
impossible in one CRS patient post-treatment (6.7%) and some patients with large polyps (sizes 3 or 4): 3/19 
pre-treatment (15.8%) and 2/17 post-treatment (11.8%).
No statistically significant differences were found between groups and in the same patient after treatment.
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Figure 1.  Patient recruitment flowchart. NC negative controls, CRS chronic rhinosinusitis patients, NP nasal 
polyps patients, PNIF peak nasal inspiratory flow, N/A not applicable. Patients lost for follow-up failed to 
show for their scheduled appointments and could not be summoned to return for evaluation. One patient was 
recruited only after treatment as the first evaluation was before the beginning of the project.
Table 1.  Patient base characteristics. Sex is shown as proportion, age as average ± standard deviation, smokers 
as percentage of smoking patients and Lund-Mackay results as median  (P25–P75). NC negative controls, CRS 
chronic rhinosinusitis patients, NP nasal polyps patients, F/M female/male. Statistically significant differences 
were found in all variables, except sex. See text for inter/intragroup comparisons.
Group/characteristic NC (n = 11) CRS (n = 16) NP (n = 19) Statistical diferences between groups
Sex (F/M) 6/5 8/8 8/11 p = 0.274
Age (years) 43 ± 13 46 ± 12 58 ± 12 p = 0.016
Smokers 5 (45%) 8 (50%) 2 (11%) p = 0.027
Lund-Mackay (right) 0 (0–1) 5.5 (4–6) 7 (5–7.5) p = 0.000
Lund-Mackay (left) 0 (0–2) 5 (4–6) 7 (6–7) p = 0.000
Lund-Mackay (total) 0 (0–3) 10 (8–12) 14 (11.5–15) p = 0.000
Table 2.  Modified Johansen scale polyp sizes. Results are shown as median  (P25–P75). Three patients showed 
complete polyp regression after treatment (score result = 0). All post-treatment changes were statistically 
significant (see text).
Polyp size Right Left Total
Pre-treatment (n = 19) 1 (1–2) 1 (1–2) 3 (2–4)
Post-treatment (n = 17) 1 (0.5–1.5) 1 (0.5–2) 2 (2–2.5)
Statistical differences after treatment p = 0.020 p = 0.023 p = 0.009
Effect sizes from the differences r =  − 0.400Medium effect size
r =  − 0.389
Medium effect size
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Polyp size vs functional results. In the pre-treatment evaluation, no significant correlation was found 
in unilateral variables, although Total Lund-Mackay scores did correlate with: global Johansen score—Spear-
man correlation coefficient (Spearman) = 0.658 (p = 0.003) and PNIF pre-decongestion—Spearman =  − 0.546 
(p = 0.000), as well as post-decongestion—Spearman =  − 0.500 (p = 0.001). This didn’t change after excluding NC 
patients from the analysis.
In the post-treatment evaluation, however, while unilateral variables didn’t correlate, global Johansen 
scores correlated with total nasal resistance (Spearman = 0.517, p = 0.048) and inspiratory Broms angle (Spear-
man = 0.518, p = 0.048), but not expiratory Broms angle (Spearman = 0.303, p = 0.292). PNIF also correlated 
with rhinomanometry in both pre- and post-decongestion analysis. Pre-decongestion results are: total nasal 
resistance (Spearman =  − 0.517, p = 0.003), inspiratory Broms angle (Spearman =  − 0.516, p = 0.004) and expir-
atory Broms angle (Spearman =  − 0.590, p = 0.001). PNIF and Johansen only correlated before decongestion 
Table 3.  PNIF values (L/min). Results are shown as median  [P25–P75]. ΔPNIF values in the CRS group only 
concern 14 individuals, given losses during follow-up (see Fig. 1). PNIF shows a trend to be smaller and vary 
less in NP patients. See text for intergroup comparisons. NC negative controls, CRS chronic rhinosinusitis 
patients, NP nasal polyps patients, N/A not applicable, ΔPNIF change in PNIF after treatment.
PNIF NC (n = 11) CRS (n = 16) NP (n = 19) Statistical diferences between groups
Effect size from differences between 
groups




(n = 19) p = 0.010
r = 1.377
Large effect size
Post-treatment N/A 120 (100–167.5)(n = 15)
90 (60–120)
(n = 17) p = 0.043
r = 0.727
Large effect size
ΔPNIF N/A 35 (0–60)(n = 14)
0 (-15–25)
(n = 17) p = 0.057
r = 0.652
Large effect size
Statistical diferences after treatment N/A p = 0.048 p = 0.674






Table 4.  Rhinomanometry results—Resistances (Pa  cm−3 s ) and Broms angles (°). Results are shown as 
median  [P25–P75]. In some cells, n values are lower than the group size because adequate readings could not be 
obtained from the patient (large polyposis) or because patients were lost for follow-up (see text). NC negative 
controls, CRS chronic rhinosinusitis patients, NP nasal polyps patients, N/A not applicable, ΔPNIF change in 
PNIF after treatment. No statistical significant differences or trends were noted and hence p-values are omitted 
for the sake of clarity (see text).
Rhinomanometry NC (N = 11) CRS (n = 16) NP (n = 19)
Pre-treatment
Right resistance 0.54 (0.47–0.59) 0.38 (0.27–1.13)(n = 15)
0.69 (0.47–1.55)
(n = 16)
Left resistance 0.66 (0.46–0.99) 0.64 (0.47–2.34)(n = 15)
0.66 (0.53–1.19)
(n = 17)
Total resistance 0.28 (0.23–0.33) 0.26 (0.19–0.45)(n = 15)
0.32 (0.26–0.56)
(n = 16)
Right Broms angle 28 (25–30) 21 (15–49)(n = 15)
35 (25–57)
(n = 16)
Left Broms angle 34 (25–45) 33 (25–67)(n = 15)
33 (28–50)
(n = 17)




Right resistance N/A 0.60 (0.40–0.94)(n = 15)
0.56 (0.37–0.77)
(n = 16)
Left resistance N/A 0.50 (0.38–0.77)(n = 15)
0.69 (0.30–0.93)
(n = 15)
Total resistance N/A 0.27 (0.17–0.38)(n = 15)
0.26 (0.21–0.32)
(n = 15)
Right Broms angle N/A 31 (22–43)(n = 15)
30 (20–38)
(n = 16)
Left Broms angle N/A 26 (21–38)(n = 15)
35 (17–43)
(n = 15)
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(Spearman =  − 0.49, p = 0.046). All correlations that were found are weak and Fig. 2 illustrates that differences 
may have reduced clinical significance, especially after decongestion.
Discussion
Overall, findings from our study suggest that PNIF and rhinomanometry can provide objective measures of nasal 
ventilation in almost all sinusitis and polyp (except patients with severe size 4 polyps). Published studies have 
presented PNIF and rhinomanometry values to compare polyp behaviour over time or after  treatment23,28–31. 
In our study we have also tried to assess whether polyp size could be a confounding factor that influences those 
results. When comparing and correlating polyp size against the several measurements and moments, we could 
only find a few weak correlations with rhinomanometry results. This suggests that differences found with these 
Figure 2.  Several graphs illustrate the effect of polyp size on nasal ventilation measures in polyp patients after 
medical treatment. Broms angles were recorded in ° and nasal resistance as Pa  cm−3 s. Box-plots are a graphical 
depiction of the dispersion measures calculated from the recordings obtained from our patients in that given 
moment and setting—Medians are represented by the thick bars and the lower and upper extremities of the 
error-bars in the box-plots are  P25 and  P75, respectively. In some patients, the values recorded fall outside the 
calculated  P25–P75 interval and these are represented as outlier circles in (a,c,d,e). These outliers stress the point 
that some patients will show particularly good or bad manometry results despite the presence of small polyps 
(Global Johansen score of 2). Correlations were mentioned in the text, although no statistical significance is 
found when comparing different global Johansen score categories. Decongestion may further abate differences 
from polyp size. Sample sizes are 0 (n = 3), 2 (n = 10) and > 2 (n = 4). (a,c,e) report pre-decongestion recordings, 
while (b,d,f) report post-decongestion recordings.
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methods may potentially reflect disease pathophysiology rather than the mechanical effect of polyp size. As such, 
PNIF and rhinomanometry should definitely be considered in future studies investigating NP pathophysiology. 
Although sample size may limit statistical power, we found significant differences and relevant effect sizes that are 
backed up by the apparently consistent and clinically relevant trend in favour of PNIF being able to discriminate 
patients without polyps from patients with polyps better than rhinomanometry. PNIF should thus be studied as 
a potential nasal ventilation biomarker of disease severity, particularly considering that it can be easily measured 
in any otolaryngology outpatient visit.
Below follows a point by point discussion of our work.
The distribution of patient characteristics in our sample is similar to that of others in the literature in the 
multiple aspects we discuss next. There is a slight male predominance in the NP group, although not the 2:1 
reported  elsewhere37. Studies in caucasian and asian populations agree that polyps tend to present in older 
 individuals38, peaking around 50–59 years of  age7. It has also been reported that in patients with sinusitis, those 
with polyps tend to be  older39,40. Our sample shows those same trends. The incidence (but not the gender propor-
tion) of smokers (32.6%) follows that of the Portuguese  population41. In a manner similar to our patients, other 
studies have also reported a higher prevalence of smokers in sinusitis  groups42, as well as a lower proportion of 
NP patients who smoke, both in national and international  cohorts40,43,44. Although Lund-Mackay scores aren’t 
used in clinical decision, they represent the extent of sinus inflammation (even though the score may be dif-
ferent from 0 in any given healthy individual). Increased scores have been associated with more symptoms and 
the presence of nasal  polyps40,45 and the same was found in our co-hort. To assess disease severity, 3- or 4-point 
scales have often been used with good inter-observer consistency in the practice of  rhinology46. These scales are 
simple to apply and easy to compare in different studies. Although polyp size may vary over time and does not 
predict treatment success, patients often tend to present with small polyps regardless of when they present for 
 evaluation23,29,30. Our patients also had predominantly small polyps.
With the exception of a score 4 polyp patient, all other individuals in our study could perform a reliable PNIF 
maneuver, despite the fact that around 7.34% unobstructed caucasians aren’t able to do  so47. Rhinomanometry 
at 150 Pa was impossible only in patients with very large polyps (15.8% pre- and 11.8% post-treatment) and also 
one CRS patient (6.7%). These results demonstrate that these methods can effectively measure nasal ventilation 
in most patients with NP.
Considering each side of the nose independently in the analysis is important because the same patient may 
have different polyp sizes. This is possible only because they are functionally separated (no septal perforations). 
This way, a broader range of nasal airways in different nasal cycle states is also represented in readings before 
decongestion. Such an analysis effectively doubles sample size in unilateral comparisons (22 nasal cavities in the 
control group, 32 in sinusitis patients and 38 in polyp patients). We have also considered polyp patients according 
to global Johansen scores distributed into three categories: 0 represents no polyps, applicable only after successful 
medical treatment (3 patients); 2 represents small intrameatal polyps (8 individuals before treatment and 10 after 
treatment); and > 2 represents patients with larger polyps that impinge on the nasal airway corridors reducing 
their cross-sectional area (11 patients before treatment and 4 patients after treatment). Despite these adjustments, 
no functional variable correlated with polyp size unilaterally before or after treatment. No statistical differences 
were found with rhinomanometry (unilateral or global measurements), despite a trend for poorer results in NP 
patients. While sample size could be the cause, we need to consider the possibility that there is an inherently 
small magnitude of differences between patients. This may have also compromised unilateral correlations with 
polyp size. Global variables, however, did show some differences. PNIF in our study appears to be lower and 
change less after treatment in NP patients, in a magnitude similar to the reports by other  authors23,29,30. This 
effect may be independent of polyp size as there were no consistent or relevant correlations with polyp scores. 
Other studies have reported a correlation of polyp size and  PNIF30, but that finding was merely a measure of 
treatment effect. We have analyzed PNIF separately before and after decongestion. Overall differences before 
and after topical decongestion were not significant, and the comparisons between groups displayed the same 
significances and followed the same trends. We opted to present pre-decongestion results as they are easier to 
obtain and compare between studies and also because they represent the natural functional state of nasal func-
tion in the patients’ everyday life. PNIF results negatively correlated with Lund-Mackay scores before treatment. 
Lower PNIF values have been associated with polyps, even when  asymptomatic5 and an increased probability 
of requiring treatment over  time23. In our study, PNIF was similar between sinusitis and polyp patients before 
treatment. However, significant changes were noted after treatment in CRS patients, but not polyp patients. 
This happened despite the changes in polyp size mentioned above and in contrast to the absence of significant 
changes in manometry results. Rhinomanometry results are similar to other reports in the  literature28,31, which 
reinforces the idea that there are naturally small differences between groups. Interestingly, if we apply to this and 
other studies the logarithmic class transformation proposed by  Vogt47, all groups will be ranked in class 1 for 
nasal obstruction (less severe), clearly pointing to a difference in the pathophysiology of symptoms in patients 
with sinonasal inflammation. This may be related to mucosal edema and inflammation induced neuropathic 
 mechanisms48. The same mechanism may also possibly explain the negative correlation between Lund-Mackay 
scores and PNIF that disappears after treatment. The correlation between Lund-Mackay and polyp size, however, 
is already  recognized49. Correlations between rhinomanometry and polyp size were only present after treatment 
and readily disappeared with decongestion. Decongestion has been shown to significantly alter polyp  size50, and 
ventilation recordings in patients with allergic  rhinitis51. We didn’t design our study to answer specifically why 
decongestion had such a small effect in manometric readings in our sinusitis and polyp patients. It’s hard to find 
answers in the literature because there are little available studies that discuss such findings in similar populations 
or study designs. At this time, we can only hypothesize that some resistance to the decongestant effect may be 
caused by mucus, epithelial barrier or endothelial changes due to the effect of inflammation or tissue remodeling.
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Broms method allows calculation of nasal airway resistance at the point where the rhinomanometric curve 
intersects a circle with radius 200 (crossing both axes at 200 Pa and 200  cm3  s−1) and the angle from a line that 
connects such point to the origin of the graph will be lower the higher the resistance in that nasal cavity. Broms 
angles were presented because they complement or may substitute nasal resistance values when they cannot be 
measured in a given patient. Broms angle was also the only dimension that we could measure when considering 
the different phases of respiration—inspiration and expiration. While inspiratory values behaved similarly to 
nasal resistance values, expiratory values never correlated with polyp size and there were no significant differ-
ences in multiple comparisons. Given that airflow patterns in the nasal cavity are different when comparing 
inspiration to expiration, we must consider the hypothesis that the difference found may represent a baseline 
pathophysiological difference. We propose that in future studies researchers make an effort to discriminate 
inspiratory from expiratory pathophysiology.
In conclusion, PNIF and rhinomanometry provide measurable results in NP and polyp size doesn’t appear to 
significantly influence recordings, especially if pre- and post-decongestion readings are obtained. The results from 
this study are consistent with other reports in the literature. It appears differences between sinusitis patients with 
or without polyps may be naturally small and PNIF may be a more useful clinical biomarker of disease severity. 
Despite the limitations in our study, its results should encourage us and other groups to continue investigating the 
clinical usefulness of PNIF and rhinomanometry, as well as their contribution to the study of NP pathophysiology.
Data availability
The datasets generated during and/or analysed during the current study are available on reasonable request from 
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